Evidence map›Paper›PMID 31365942›Full record

Observational studyThrombosis and haemostasis2019

Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry.

Birgit Vogel, Jaya Chandrasekhar, Usman Baber, Ioannis Mastoris, Samantha Sartori, Melissa Aquino, Mitchell W Krucoff, David J Moliterno, Timothy D Henry, Giora Weisz and 16 more

Erratum issuedAbstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Thrombosis and haemostasis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors.

Birgit VogelThe Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States.
Jaya ChandrasekharThe Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States.
Usman BaberThe Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States.
Ioannis MastorisThe Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States.
Samantha SartoriThe Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States.
Melissa AquinoThe Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States.
Mitchell W KrucoffDuke University School of Medicine, Durham, North Carolina, United States.
David J MoliternoUniversity of Kentucky, Lexington, Kentucky, United States.
Timothy D HenryThe Carl and Edyth Lindner Center for Research and Education, The Christ Hospital, Cincinnati, Ohio, United States.ORCID 0000-0003-1123-0533
Giora WeiszMontefiore Medical Center, New York, New York, United States.
C Michael GibsonDivision of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States.
Ioannis IakovouOnassis Cardiac Surgery Centre, Athens, Greece.
Annapoorna S KiniThe Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States.
Serdar FarhanThe Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States.
Sabato SorrentinoThe Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States.
Michela FaggioniThe Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States.
Antonio ColomboSan Raffaele Scientific Institute, Milan, Italy.
Philippe Gabriel StegUniversité Paris-Diderot, Sorbonne Paris-Cité, Paris, France.
Bernhard WitzenbichlerHelios Amper-Klinikum, Dachau, Germany.
Alaide ChieffoSan Raffaele Scientific Institute, Milan, Italy.
David J CohenSt. Luke's Mid America Heart Institute, University of Missouri-Kansas City, Kansas City, Missouri, United States.
Thomas StuckeyMoses Cone Heart and Vascular Center, LeBauer Cardiovascular Research Foundation, Greensboro, North Carolina, United States.
Cono AritiLondon School of Hygiene and Tropical Medicine, London, United Kingdom.
George D DangasThe Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States.
Stuart PocockLondon School of Hygiene and Tropical Medicine, London, United Kingdom.
Roxana MehranThe Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundData on geographical variations in dual antiplatelet therapy (DAPT) cessation and the impact on outcomes after percutaneous coronary intervention (PCI) are limited. We sought to evaluate geographical patterns of DAPT cessation and associated outcomes in patients undergoing PCI in the United States versus Europe.

methodsAnalyzing data from the PARIS registry, we studied 3,660 U.S. patients (72.9%) and 1,358 European patients (27.1%) that underwent PCI with stent implantation. DAPT cessation was classified as physician-recommended discontinuation, interruption (< 14 days), or disruption due to bleeding or noncompliance. The primary endpoint was 2-year major adverse cardiovascular events (MACE) defined as a composite of cardiac death, stent thrombosis, myocardial infarction, or target lesion revascularization.

resultsCardiovascular risk factors were more common in the United States, whereas procedural complexity was greater in Europe. The incidence of 2-year DAPT discontinuation was significantly lower in U.S. versus European patients (30.7% vs. 65.6%;

conclusionDAPT cessation patterns, along with clinical and angiographic risk, vary substantially between PCI patients in the U.S. versus Europe. Despite such differences, cardiovascular risk associated with DAPT cessation remains uniform.

Indexed as

Percutaneous Coronary InterventionAgedAspirinCardiovascular DiseasesCoronary Artery DiseaseDrug-Eluting StentsEuropeFemaleFollow-Up StudiesGeographyHeart Valve ProsthesisHemorrhageHumansMaleMiddle AgedMyocardial InfarctionAspirinPlatelet Aggregation Inhibitors

Identifiers

PMID31365942

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.